The global distribution of the custom myoelectric orthosis will begin in select markets in North America and Germany.
The MyoPro, based on technology developed at the Massachusetts Institute of Technology, is used to help support and restore function for people who have a paralyzed arm as a result of a stroke, spinal cord injury, nerve damage such as brachial plexus injury, or progressive conditions such as multiple sclerosis or ALS, according to a media release from Austin, Tex-headquartered Ottobock and Cambridge, Mass-based Myomo.
“Ottobock is committed to providing orthotic solutions to drive successful patient outcomes and meet the needs of the orthotist,” says Chris Nolan, vice president of orthotics for Ottobock North America, in the release. “Our partnership with Myomo will enable Ottobock to address the unmet needs of individuals with upper extremity paralysis with the MyoPro orthotic product line. We look forward to providing this innovative technology to help people maintain or regain their freedom of movement.”
Frank Bomers, global head of orthotics for Ottobock, adds, “Ottobock is excited to leverage the strength of our global sales organization to represent this innovative treatment for the patients we serve.”
“We are pleased to enter into this agreement with Ottobock so that we can broaden distribution of the MyoPro product line in the US and in international markets served by Ottobock,” states Paul R. Gudonis, CEO of Myomo.
[Source(s): Ottobock, Myomo Inc]